Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

Levofloxacin In The Treatment Of Children With Recurrent And/or Persistent Acute Otitis Media

This study has been completed.
Sponsor:
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT00051753
First received: January 16, 2003
Last updated: January 7, 2011
Last verified: January 2011
History of Changes

January 16, 2003
January 7, 2011
November 2002
Not Provided
Clinical response (cured versus not cured) at Visit 3 (2 to 5 days after last dose).
Not Provided
Complete list of historical versions of study NCT00051753 on ClinicalTrials.gov Archive Site
Clinical success (cured and improved versus failed) rate at Visit 3 (2 to 5 days after the last dose) and Visit 4 (10 to 17 days after the last dose); clinical cure rate at Visit 4 (10 to 17 days after the last dose); safety evaluations
Not Provided
Not Provided
Not Provided
 
Levofloxacin In The Treatment Of Children With Recurrent And/or Persistent Acute Otitis Media
A Multicenter, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Levofloxacin in the Treatment of Children Who Have Recurrent and/or Persistent Acute Otitis Media
The purpose of this study is to demonstrate non-inferiority of levofloxacin compared with amoxicillin/clavulanate on the clinical response at the end of therapy in infants and children who have recurrent and/or persistent acute otitis media.
This is a randomized, active-comparator, multicenter study consisting of 3 phases: a Pretreatment (Screening) Phase, a Treatment Phase, and a Posttreatment Phase. Subject eligibility will be determined at the screening visit based on signs and symptoms of acute otitis media (e.g., middle ear effusion, acute inflammation, acute purulent otorrhea) and criteria for recurrent and/or persistent acute otitis media. Eligible subjects will be randomized and drug will be dispensed by a study coordinator who will instruct parents and the subject about the importance of not revealing the assigned therapy to the subject's evaluator. Each subject will have an evaluator who will remain blinded to the subject's therapy throughout the study. Clinical assessments performed by a blinded evaluator at several time points throughout the study will be used to evaluate efficacy. Safety will be evaluated throughout the study by assessment of adverse events and changes in physical examinations (including musculoskeletal examination with evaluation of joints), vital signs, and clinical laboratory findings. Supplementary safety evaluations for musculoskeletal adverse events will be performed throughout the study. All subjects who enroll in this study and take at least 1 dose of levofloxacin or amoxicillin/clavulanate will be eligible to rollover into a long-term surveillance study primarily focused on the musculoskeletal system. The purpose of this study is to demonstrate non-inferiority of levofloxacin compared with amoxicillin/clavulanate on the clinical response at the end of therapy in infants and children who have recurrent and/or persistent acute otitis media. Either levofloxacin 10 mg/kg twice daily for 10 days (maximum daily dose of 500 mg) or amoxicillin/clavulanate (14:1) 45 mg amoxicillin/kg twice daily for 10 days (maximum daily dose of 3600 mg amoxicillin). Both study drugs will be given orally as a liquid suspension formulation
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Otitis Media
Drug: levofloxacin; amoxicillin/clavulanate
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1643
May 2005
Not Provided

Inclusion Criteria:

  • Males or females, aged > or equal to 6 months to < 5 years
  • Clinical signs and symptoms of otitis media including middle ear effusion and acute inflammation or acute purulent otorrhea
  • At risk for difficult to treat Acute Otitis Media (AOM) is defined as having one of the following: recurrent Otitis Media (OM) as defined by 3 or more episodes in last 6 months or 4 or more episodes in past year or persistent OM as defined by evidence of AOM on 3rd day after starting any antimicrobial regimen
  • Written consent/assent
  • Have not participated in an experimental drug or medical device trial within 30 days prior to start of study.

Exclusion Criteria:

  • History of hypersensitivity or serious reaction to any quinolone
  • Tympanostomy tube in the affected ear
  • Requires use of systemic antibiotic other than study drug
  • Has a serious bacterial infection in addition to AOM that may interfere with assessment of their clinical response
  • Diagnosed with bacterial meningitis
  • Abnormal renal function defined as serum creatinine >0.5 mg/dL in infants 6 months or older and 0.8 mg/dL in children between 1 and 5 years of age
  • History or presence of arthropathy or periarticular disease or any other musculoskeletal signs or symptoms that may confound a future safety exam of MS events
  • Has a high probability of death during the study
  • Poorly controlled seizure disorder or at risk for seizures
  • HIV infection requiring pneumocystis carinii pneumonia prophylaxis
  • Chronic use of corticosteroids 2mg/kg or more or 20mg/day for 14 or more days
  • Amoxicillin/clavulanate (90 mg/kg/day) use within 3 days before the first dose of the study drug
  • Previous participation in this protocol or another levofloxacin clinical study
  • Employees of the investigator or study center with direct involvement in the study
  • Family members are also excluded
Both
6 Months to 5 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
Argentina,   Brazil,   Costa Rica,   Mexico,   United States
 
NCT00051753
CR004168
Not Provided
Not Provided
Not Provided
Not Provided
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Not Provided
Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP